These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17924963)

  • 21. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling.
    Risbridger GP; Ellem SJ; McPherson SJ
    J Mol Endocrinol; 2007 Sep; 39(3):183-8. PubMed ID: 17766643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion.
    Platet N; Cathiard AM; Gleizes M; Garcia M
    Crit Rev Oncol Hematol; 2004 Jul; 51(1):55-67. PubMed ID: 15207254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research.
    Klein RD
    Mutat Res; 2005 Aug; 576(1-2):111-9. PubMed ID: 15885713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention.
    Jordan VC
    Cancer Res; 2009 Feb; 69(4):1243-54. PubMed ID: 19208829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.
    Ao M; Franco OE; Park D; Raman D; Williams K; Hayward SW
    Cancer Res; 2007 May; 67(9):4244-53. PubMed ID: 17483336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.
    Caporali A; Davalli P; Astancolle S; D'Arca D; Brausi M; Bettuzzi S; Corti A
    Carcinogenesis; 2004 Nov; 25(11):2217-24. PubMed ID: 15358631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogens and aspects of prostate disease.
    Prezioso D; Denis LJ; Klocker H; Sciarra A; Reis M; Naber K; Lobel B; Pacik D; Griffiths K
    Int J Urol; 2007 Jan; 14(1):1-16. PubMed ID: 17199853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis.
    Bosland MC
    Ann N Y Acad Sci; 2006 Nov; 1089():168-76. PubMed ID: 17261765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
    Abdou AG; Aiad HA; Sultan SM
    APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of stromal-epithelial interaction in normal and malignant growth.
    Chung LW
    Cancer Surv; 1995; 23():33-42. PubMed ID: 7621472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of steroid hormones in prostate cancer.
    Wilding G
    Cancer Surv; 1992; 14():113-30. PubMed ID: 1423327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of aromatic hydroxylation of 11 beta-substituted estrogens with morphological transformation in vitro but not with in vivo tumor induction by these hormones.
    Liehr JG; Purdy RH; Baran JS; Nutting EF; Colton F; Randerath E; Randerath K
    Cancer Res; 1987 May; 47(10):2583-8. PubMed ID: 3032410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.
    Latil A; Bièche I; Vidaud D; Lidereau R; Berthon P; Cussenot O; Vidaud M
    Cancer Res; 2001 Mar; 61(5):1919-26. PubMed ID: 11280747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of chemoprevention for prostate cancer development: experimental in vivo approaches to chemoprevention.
    Shirai T
    Pathol Int; 2008 Jan; 58(1):1-16. PubMed ID: 18067635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human prostate cancer risk factors.
    Bostwick DG; Burke HB; Djakiew D; Euling S; Ho SM; Landolph J; Morrison H; Sonawane B; Shifflett T; Waters DJ; Timms B
    Cancer; 2004 Nov; 101(10 Suppl):2371-490. PubMed ID: 15495199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer chemoprevention: current status and future prospects.
    Gupta S
    Toxicol Appl Pharmacol; 2007 Nov; 224(3):369-76. PubMed ID: 17189645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis.
    Isaacs JT
    Cancer Res; 1984 Dec; 44(12 Pt 1):5785-96. PubMed ID: 6498839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines.
    Webber MM; Bello D; Quader S
    Prostate; 1996 Dec; 29(6):386-94. PubMed ID: 8977636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of human prostate cancer models for chemoprevention and experimental therapeutics studies.
    Chung LW; Zhau HE; Wu TT
    J Cell Biochem Suppl; 1997; 28-29():174-81. PubMed ID: 9589364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.